The	O
QUIDAM	B:C0033522
study	I:C0033522
:	O
Hydroquinidine	O
therapy	O
for	O
the	O
management	O
of	O
Brugada	O
syndrome	I:C1142166
patients	O
at	O
high	O
arrhythmic	O
risk	O
.	O

The	O
QUIDAM	O
study	I:C0033522
:	O
Hydroquinidine	B:C0063103
therapy	O
for	O
the	O
management	O
of	O
Brugada	O
syndrome	I:C1142166
patients	O
at	O
high	O
arrhythmic	O
risk	O
.	O

The	O
QUIDAM	O
study	I:C0033522
:	O
Hydroquinidine	O
therapy	B:C0087111
for	O
the	O
management	O
of	O
Brugada	O
syndrome	I:C1142166
patients	O
at	O
high	O
arrhythmic	O
risk	O
.	O

The	O
QUIDAM	O
study	I:C0033522
:	O
Hydroquinidine	O
therapy	O
for	O
the	O
management	B:C0376636
of	O
Brugada	O
syndrome	I:C1142166
patients	O
at	O
high	O
arrhythmic	O
risk	O
.	O

The	O
QUIDAM	O
study	I:C0033522
:	O
Hydroquinidine	O
therapy	O
for	O
the	O
management	O
of	O
Brugada	B:C1142166
syndrome	I:C1142166
patients	O
at	O
high	O
arrhythmic	O
risk	O
.	O

The	O
QUIDAM	O
study	I:C0033522
:	O
Hydroquinidine	O
therapy	O
for	O
the	O
management	O
of	O
Brugada	O
syndrome	I:C1142166
patients	O
at	O
high	O
arrhythmic	B:C0085612
risk	O
.	O

Although	O
the	O
implantable	B:C0162589
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
(	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
)	O
remains	O
the	O
main	O
therapy	O
for	O
Brugada	O
syndrome	I:C1142166
(	O
Brugada	O
syndrome	I:C1142166
)	O
,	O
it	O
does	O
not	O
reduce	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
.	O

Although	O
the	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
(	O
implantable	B:C0162589
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
)	O
remains	O
the	O
main	O
therapy	O
for	O
Brugada	O
syndrome	I:C1142166
(	O
Brugada	O
syndrome	I:C1142166
)	O
,	O
it	O
does	O
not	O
reduce	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
.	O

Although	O
the	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
(	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
)	O
remains	O
the	O
main	O
therapy	B:C0087111
for	O
Brugada	O
syndrome	I:C1142166
(	O
Brugada	O
syndrome	I:C1142166
)	O
,	O
it	O
does	O
not	O
reduce	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
.	O

Although	O
the	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
(	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
)	O
remains	O
the	O
main	O
therapy	O
for	O
Brugada	B:C1142166
syndrome	I:C1142166
(	O
Brugada	O
syndrome	I:C1142166
)	O
,	O
it	O
does	O
not	O
reduce	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
.	O

Although	O
the	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
(	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
)	O
remains	O
the	O
main	O
therapy	O
for	O
Brugada	O
syndrome	I:C1142166
(	O
Brugada	B:C1142166
syndrome	I:C1142166
)	O
,	O
it	O
does	O
not	O
reduce	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
.	O

Although	O
the	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
(	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
)	O
remains	O
the	O
main	O
therapy	O
for	O
Brugada	O
syndrome	I:C1142166
(	O
Brugada	O
syndrome	I:C1142166
)	O
,	O
it	O
does	O
not	O
reduce	O
life	B:C2826244
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
.	O

Although	O
the	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
(	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
)	O
remains	O
the	O
main	O
therapy	O
for	O
Brugada	O
syndrome	I:C1142166
(	O
Brugada	O
syndrome	I:C1142166
)	O
,	O
it	O
does	O
not	O
reduce	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	B:C0085612
arrhythmia	I:C0085612
.	O

Based	O
on	O
pathophysiologic	O
mechanisms	O
,	O
hydroquinidine	B:C0063103
(	O
hydroquinidine	O
)	O
has	O
been	O
suggested	O
for	O
effective	O
prevention	O
of	O
arrhythmia	O
.	O

Based	O
on	O
pathophysiologic	O
mechanisms	O
,	O
hydroquinidine	O
(	O
hydroquinidine	B:C0063103
)	O
has	O
been	O
suggested	O
for	O
effective	O
prevention	O
of	O
arrhythmia	O
.	O

Based	O
on	O
pathophysiologic	O
mechanisms	O
,	O
hydroquinidine	O
(	O
hydroquinidine	O
)	O
has	O
been	O
suggested	O
for	O
effective	O
prevention	O
of	O
arrhythmia	B:C0085612
.	O

The	O
purpose	O
of	O
this	O
study	B:C2603343
was	O
to	O
provide	O
evidence	O
-	O
based	O
data	O
supporting	O
hydroquinidine	O
use	O
to	O
prevent	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
in	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
with	O
Brugada	O
syndrome	I:C1142166
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
provide	O
evidence	O
-	O
based	O
data	O
supporting	O
hydroquinidine	B:C0063103
use	O
to	O
prevent	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
in	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
with	O
Brugada	O
syndrome	I:C1142166
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
provide	O
evidence	O
-	O
based	O
data	O
supporting	O
hydroquinidine	O
use	O
to	O
prevent	O
life	B:C2826244
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
in	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
with	O
Brugada	O
syndrome	I:C1142166
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
provide	O
evidence	O
-	O
based	O
data	O
supporting	O
hydroquinidine	O
use	O
to	O
prevent	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	B:C0085612
arrhythmia	I:C0085612
in	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
with	O
Brugada	O
syndrome	I:C1142166
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
provide	O
evidence	O
-	O
based	O
data	O
supporting	O
hydroquinidine	O
use	O
to	O
prevent	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
in	O
high	B:C0332167
-	I:C0332167
risk	I:C0332167
patients	O
with	O
Brugada	O
syndrome	I:C1142166
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
provide	O
evidence	O
-	O
based	O
data	O
supporting	O
hydroquinidine	O
use	O
to	O
prevent	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
in	O
high	O
-	I:C0332167
risk	I:C0332167
patients	O
with	O
Brugada	B:C1142166
syndrome	I:C1142166
.	O

We	O
performed	O
a	O
prospective	B:C0013072
multicenter	I:C0013072
randomized	I:C0013072
(	I:C0013072
HQ	I:C0013072
vs	I:C0013072
placebo	I:C0013072
)	I:C0013072
double	I:C0013072
-	I:C0013072
blind	I:C0013072
study	I:C0013072
with	O
two	O
18	O
-	O
month	O
crossover	O
phases	O
in	O
patients	O
with	O
Brugada	O
syndrome	I:C1142166
and	O
implanted	O
with	O
an	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
.	O

We	O
performed	O
a	O
prospective	O
multicenter	I:C0013072
randomized	I:C0013072
(	I:C0013072
HQ	I:C0013072
vs	I:C0013072
placebo	I:C0013072
)	I:C0013072
double	I:C0013072
-	I:C0013072
blind	I:C0013072
study	I:C0013072
with	O
two	O
18	O
-	O
month	O
crossover	O
phases	O
in	O
patients	O
with	O
Brugada	B:C1142166
syndrome	I:C1142166
and	O
implanted	O
with	O
an	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
.	O

We	O
performed	O
a	O
prospective	O
multicenter	I:C0013072
randomized	I:C0013072
(	I:C0013072
HQ	I:C0013072
vs	I:C0013072
placebo	I:C0013072
)	I:C0013072
double	I:C0013072
-	I:C0013072
blind	I:C0013072
study	I:C0013072
with	O
two	O
18	O
-	O
month	O
crossover	O
phases	O
in	O
patients	O
with	O
Brugada	O
syndrome	I:C1142166
and	O
implanted	B:C0021107
with	O
an	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
.	O

We	O
performed	O
a	O
prospective	O
multicenter	I:C0013072
randomized	I:C0013072
(	I:C0013072
HQ	I:C0013072
vs	I:C0013072
placebo	I:C0013072
)	I:C0013072
double	I:C0013072
-	I:C0013072
blind	I:C0013072
study	I:C0013072
with	O
two	O
18	O
-	O
month	O
crossover	O
phases	O
in	O
patients	O
with	O
Brugada	O
syndrome	I:C1142166
and	O
implanted	O
with	O
an	O
implantable	B:C0162589
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
.	O

Thirty	O
-	O
four	O
(	O
68	O
%	O
)	O
presented	O
hydroquinidine	B:C0063103
-	O
related	O
side	O
effects	I:C0879626
,	O
mainly	O
gastrointestinal	O
,	O
which	O
led	O
to	O
discontinuation	O
of	I:C4288399
the	I:C4288399
therapy	I:C4288399
in	O
13	O
(	O
26	O
%	O
)	O
.	O

Thirty	O
-	O
four	O
(	O
68	O
%	O
)	O
presented	O
hydroquinidine	O
-	O
related	O
side	B:C0879626
effects	I:C0879626
,	O
mainly	O
gastrointestinal	O
,	O
which	O
led	O
to	O
discontinuation	O
of	I:C4288399
the	I:C4288399
therapy	I:C4288399
in	O
13	O
(	O
26	O
%	O
)	O
.	O

Thirty	O
-	O
four	O
(	O
68	O
%	O
)	O
presented	O
hydroquinidine	O
-	O
related	O
side	O
effects	I:C0879626
,	O
mainly	O
gastrointestinal	O
,	O
which	O
led	O
to	O
discontinuation	B:C4288399
of	I:C4288399
the	I:C4288399
therapy	I:C4288399
in	O
13	O
(	O
26	O
%	O
)	O
.	O

hydroquinidine	B:C0063103
lengthened	O
the	O
QTc	O
interval	O
(	O
409	O
±	O
32	O
ms	O
vs	O
433	O
±	O
37	O
ms	O
;	O
P	O
=	O
.027	O
)	O
and	O
increased	O
repolarization	O
dispersion	O
as	O
evaluated	O
by	O
Tpe	O
max	I:C0239242
in	O
precordial	O
leads	O
(	O
89	O
±	O
15	O
ms	O
vs	O
108	O
±	O
27	O
ms	O
;	O
P	O
<.0001	O
)	O
with	O
no	O
significant	O
changes	O
in	O
J	O
-	O
point	O
elevation	O
.	O

hydroquinidine	O
lengthened	O
the	O
QTc	O
interval	O
(	O
409	O
±	O
32	O
ms	O
vs	O
433	O
±	O
37	O
ms	O
;	O
P	O
=	O
.027	O
)	O
and	O
increased	O
repolarization	B:C3537202
dispersion	O
as	O
evaluated	O
by	O
Tpe	O
max	I:C0239242
in	O
precordial	O
leads	O
(	O
89	O
±	O
15	O
ms	O
vs	O
108	O
±	O
27	O
ms	O
;	O
P	O
<.0001	O
)	O
with	O
no	O
significant	O
changes	O
in	O
J	O
-	O
point	O
elevation	O
.	O

hydroquinidine	O
lengthened	O
the	O
QTc	O
interval	O
(	O
409	O
±	O
32	O
ms	O
vs	O
433	O
±	O
37	O
ms	O
;	O
P	O
=	O
.027	O
)	O
and	O
increased	O
repolarization	O
dispersion	B:C0332624
as	O
evaluated	O
by	O
Tpe	O
max	I:C0239242
in	O
precordial	O
leads	O
(	O
89	O
±	O
15	O
ms	O
vs	O
108	O
±	O
27	O
ms	O
;	O
P	O
<.0001	O
)	O
with	O
no	O
significant	O
changes	O
in	O
J	O
-	O
point	O
elevation	O
.	O

hydroquinidine	O
lengthened	O
the	O
QTc	O
interval	O
(	O
409	O
±	O
32	O
ms	O
vs	O
433	O
±	O
37	O
ms	O
;	O
P	O
=	O
.027	O
)	O
and	O
increased	O
repolarization	O
dispersion	O
as	O
evaluated	O
by	O
Tpe	B:C0239242
max	I:C0239242
in	O
precordial	O
leads	O
(	O
89	O
±	O
15	O
ms	O
vs	O
108	O
±	O
27	O
ms	O
;	O
P	O
<.0001	O
)	O
with	O
no	O
significant	O
changes	O
in	O
J	O
-	O
point	O
elevation	O
.	O

hydroquinidine	O
lengthened	O
the	O
QTc	O
interval	O
(	O
409	O
±	O
32	O
ms	O
vs	O
433	O
±	O
37	O
ms	O
;	O
P	O
=	O
.027	O
)	O
and	O
increased	O
repolarization	O
dispersion	O
as	O
evaluated	O
by	O
Tpe	O
max	I:C0239242
in	O
precordial	O
leads	O
(	O
89	O
±	O
15	O
ms	O
vs	O
108	O
±	O
27	O
ms	O
;	O
P	O
<.0001	O
)	O
with	O
no	O
significant	O
changes	O
in	O
J	O
-	O
point	O
elevation	B:C0702240
.	O

During	O
the	O
36	O
-	O
month	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
,	O
1	O
appropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
(	O
0.97	O
%	O
event	O
per	O
year	O
)	O
,	O
1	O
self	O
-	O
terminating	O
ventricular	O
fibrillation	I:C0042510
,	O
and	O
1	O
inappropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
occurred	O
under	O
placebo	O
therapy	I:C0032042
.	O

During	O
the	O
36	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
1	O
appropriate	O
implantable	B:C0162589
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
(	O
0.97	O
%	O
event	O
per	O
year	O
)	O
,	O
1	O
self	O
-	O
terminating	O
ventricular	O
fibrillation	I:C0042510
,	O
and	O
1	O
inappropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
occurred	O
under	O
placebo	O
therapy	I:C0032042
.	O

During	O
the	O
36	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
1	O
appropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	B:C0036974
(	O
0.97	O
%	O
event	O
per	O
year	O
)	O
,	O
1	O
self	O
-	O
terminating	O
ventricular	O
fibrillation	I:C0042510
,	O
and	O
1	O
inappropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
occurred	O
under	O
placebo	O
therapy	I:C0032042
.	O

During	O
the	O
36	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
1	O
appropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
(	O
0.97	O
%	O
event	O
per	O
year	O
)	O
,	O
1	O
self	O
-	O
terminating	O
ventricular	B:C0042510
fibrillation	I:C0042510
,	O
and	O
1	O
inappropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
occurred	O
under	O
placebo	O
therapy	I:C0032042
.	O

During	O
the	O
36	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
1	O
appropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
(	O
0.97	O
%	O
event	O
per	O
year	O
)	O
,	O
1	O
self	O
-	O
terminating	O
ventricular	O
fibrillation	I:C0042510
,	O
and	O
1	O
inappropriate	O
implantable	B:C0162589
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
occurred	O
under	O
placebo	O
therapy	I:C0032042
.	O

During	O
the	O
36	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
1	O
appropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
(	O
0.97	O
%	O
event	O
per	O
year	O
)	O
,	O
1	O
self	O
-	O
terminating	O
ventricular	O
fibrillation	I:C0042510
,	O
and	O
1	O
inappropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	B:C0036974
occurred	O
under	O
placebo	O
therapy	I:C0032042
.	O

During	O
the	O
36	O
-	O
month	O
follow	O
-	I:C1522577
up	I:C1522577
,	O
1	O
appropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
(	O
0.97	O
%	O
event	O
per	O
year	O
)	O
,	O
1	O
self	O
-	O
terminating	O
ventricular	O
fibrillation	I:C0042510
,	O
and	O
1	O
inappropriate	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
shock	O
occurred	O
under	O
placebo	B:C0032042
therapy	I:C0032042
.	O

No	O
arrhythmic	B:C0085612
events	O
were	O
reported	O
under	O
hydroquinidine	O
therapy	O
.	O

No	O
arrhythmic	O
events	O
were	O
reported	O
under	O
hydroquinidine	B:C0063103
therapy	O
.	O

No	O
arrhythmic	O
events	O
were	O
reported	O
under	O
hydroquinidine	O
therapy	B:C0087111
.	O

Although	O
hydroquinidine	B:C0063103
seems	O
to	O
be	O
effective	O
in	O
preventing	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
,	O
it	O
could	O
not	O
be	O
an	O
alternative	O
for	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
implantation	O
.	O

Although	O
hydroquinidine	O
seems	O
to	O
be	O
effective	O
in	O
preventing	O
life	B:C2826244
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
,	O
it	O
could	O
not	O
be	O
an	O
alternative	O
for	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
implantation	O
.	O

Although	O
hydroquinidine	O
seems	O
to	O
be	O
effective	O
in	O
preventing	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	B:C0085612
arrhythmia	I:C0085612
,	O
it	O
could	O
not	O
be	O
an	O
alternative	O
for	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
implantation	O
.	O

Although	O
hydroquinidine	O
seems	O
to	O
be	O
effective	O
in	O
preventing	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
,	O
it	O
could	O
not	O
be	O
an	O
alternative	O
for	O
implantable	B:C0162589
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
implantation	O
.	O

Although	O
hydroquinidine	O
seems	O
to	O
be	O
effective	O
in	O
preventing	O
life	O
-	I:C2826244
threatening	I:C2826244
ventricular	O
arrhythmia	I:C0085612
,	O
it	O
could	O
not	O
be	O
an	O
alternative	O
for	O
implantable	O
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
implantation	B:C0021107
.	O

Its	O
frequent	O
side	B:C0879626
effects	I:C0879626
greatly	O
reduce	O
its	O
probable	O
compliance	O
and	O
therefore	O
do	O
not	O
reveal	O
a	O
significant	O
effect	O
.	O

hydroquinidine	B:C0063103
increases	O
repolarization	O
dispersal	O
with	O
no	O
changes	O
in	O
Brugada	O
syndrome	I:C1142166
pattern	O
,	O
which	O
could	O
indicate	O
a	O
more	O
complex	O
action	O
of	O
hydroquinidine	O
than	O
its	O
Ito	O
blocking	O
effect	O
alone	O
.	O

hydroquinidine	O
increases	O
repolarization	B:C3537202
dispersal	O
with	O
no	O
changes	O
in	O
Brugada	O
syndrome	I:C1142166
pattern	O
,	O
which	O
could	O
indicate	O
a	O
more	O
complex	O
action	O
of	O
hydroquinidine	O
than	O
its	O
Ito	O
blocking	O
effect	O
alone	O
.	O

hydroquinidine	O
increases	O
repolarization	O
dispersal	B:C0332624
with	O
no	O
changes	O
in	O
Brugada	O
syndrome	I:C1142166
pattern	O
,	O
which	O
could	O
indicate	O
a	O
more	O
complex	O
action	O
of	O
hydroquinidine	O
than	O
its	O
Ito	O
blocking	O
effect	O
alone	O
.	O

hydroquinidine	O
increases	O
repolarization	O
dispersal	O
with	O
no	O
changes	O
in	O
Brugada	B:C1142166
syndrome	I:C1142166
pattern	O
,	O
which	O
could	O
indicate	O
a	O
more	O
complex	O
action	O
of	O
hydroquinidine	O
than	O
its	O
Ito	O
blocking	O
effect	O
alone	O
.	O

hydroquinidine	O
increases	O
repolarization	O
dispersal	O
with	O
no	O
changes	O
in	O
Brugada	O
syndrome	I:C1142166
pattern	O
,	O
which	O
could	O
indicate	O
a	O
more	O
complex	O
action	O
of	O
hydroquinidine	B:C0063103
than	O
its	O
Ito	O
blocking	O
effect	O
alone	O
.	O

